Skip to content

Alaunos Therapeutics, Inc.

TCRT

CIK 0001107421

← back to feed
Revenue (TTM)
$2K
−50.0% YoY Q1 May 2026
Net Income (TTM)
−$4.29M
+10.8% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.44
+24.7% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-216,500.0%
Q1 May 2026
Net Margin
-214,450.0%
Q1 May 2026
Free Cash Flow (TTM)
−$13.91M
Q1 May 2026
Cash
$354K
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
24.42M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings